Netflix Reports Q4 Results, Q1 Guidance Misses Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: Benzinga
- Earnings Performance: Netflix's Q4 earnings report revealed revenue of $12.16 billion, exceeding expectations, yet its Q1 guidance of $12.16 billion fell short of the $12.19 billion consensus, causing shares to drop 5.7% to $82.32 in pre-market trading.
- Earnings Per Share Outlook: The company anticipates Q1 earnings per share of 76 cents, below the consensus estimate of 81 cents, indicating pressure on user growth and profitability, which may undermine investor confidence.
- Other Stock Movements: Erasca Inc announced a proposed $150 million public offering, leading to a 6.2% decline in its pre-market share price to $9.20, highlighting market sensitivity to new stock issuances.
- Market Reaction: Kraft Heinz Co shares fell 5.3% to $22.51 as Berkshire Hathaway filed to sell up to 325 million shares, intensifying market concerns regarding its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 18.360
Low
2.00
Averages
5.50
High
11.00
Current: 18.360
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Faces Federal Securities Class Action Deadline
- Lawsuit Background: Erasca, Inc. is facing a federal securities class action for allegedly making false statements about its oncology drug ERAS-0015 during the class period from January 14, 2025, to April 26, 2026, failing to disclose improper comparisons with competitor RMC-6236, which may lead to patent and trade secret disputes.
- Stock Price Volatility: On April 27, 2026, Erasca's stock price dropped by $2.34, approximately 11%, from $21.49 to $19.15, following a patent infringement allegation from RevMed, indicating the market's sensitivity to legal risks associated with the company.
- Clinical Data Disclosure: On the same day, Erasca reported that a patient treated with ERAS-0015 died about a month after starting treatment, classified as a severe adverse reaction, which heightened investor concerns and led to a further decline of $9.25, or about 48%, in stock price the following day.
- Investor Action Advisory: Investors in Erasca are reminded to apply by August 10, 2026, to become lead plaintiffs in the pending class action, emphasizing the importance of timely action to protect their rights and interests in the litigation.
See More
Erasca Faces Securities Class Action After 48% Stock Plunge
- Stock Plunge: Erasca's stock plummeted by $9.25 (-48%) following allegations of patent infringement, resulting in a loss of over $2.8 billion in market capitalization, which severely undermines investor confidence and may trigger broader market concerns.
- Legal Action: Hagens Berman is investigating whether Erasca intentionally misled investors regarding the safety of ERAS-0015 and its competitive positioning in the oncology market, which could lead to further legal ramifications.
- Patent Dispute: The company is accused of improperly comparing its ERAS-0015 to Revolution Medicines' RMC-6236 without disclosing potential intellectual property disputes, which may impact future research and market strategies.
- Patient Incident: The disclosure of a patient's adverse event and subsequent death after receiving ERAS-0015 has intensified scrutiny over the product's safety profile, potentially leading to further regulatory investigations.
See More
Erasca Faces Class Action Lawsuit from Investors
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Erasca in the Southern District of California on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, alleging the company failed to disclose critical adverse facts that may have led to investor losses.
- False Statements Allegations: The lawsuit claims that Erasca made false and misleading statements regarding the preclinical data of ERAS-0015, asserting that improper comparisons to Revolution Medicines placed the company at risk of patent and trade secret violations, misleading investors about the drug's prospects.
- Stock Price Plummet: Following the disclosure on April 28, 2026, that Erasca received a letter from Revolution Medicines alleging patent infringement related to ERAS-0015, the stock price plummeted from $19.15 to $9.90, a decline of approximately 48%, significantly impacting investor confidence.
- Investor Action Encouraged: Affected investors are urged to apply by August 10, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering no-cost consultations to help investors understand their rights and options.
See More
Multiple Companies Face Class Action Lawsuits
- Via Transportation Class Action: From September 2025 to June 2026, Via Transportation is accused of failing to disclose a decline in annual recurring revenue per customer and regulatory issues, misleading investors about the company's prospects and potentially hindering its expansion strategy in Germany.
- Zillow Class Action: During the period from February 2025 to May 2026, Zillow allegedly failed to disclose that its agreement with Redfin was an acquisition rather than a partnership, increasing its exposure to antitrust legal risks, which could negatively impact the company's reputation and stock price.
- ADMA Biologics Class Action: From August 2024 to March 2026, ADMA is accused of engaging in undisclosed related party transactions and channel stuffing, leading to distorted financial reporting that could undermine investor confidence and future financing capabilities.
- Erasca Class Action: Between January 2025 and April 2026, Erasca is alleged to have failed to disclose improper comparisons in its preclinical data, risking violations of patent and trade secret protections, which could affect the company's future R&D and market competitiveness.
See More
Erasca Shares Plunge 53.9% Following Class Action Announcement
- Stock Price Collapse: Erasca's shares plummeted from $21.49 on April 24, 2026, to $9.90 by April 28, resulting in an $11.59 per share loss and a 53.9% decline, indicating a severe erosion of market confidence in the company's prospects.
- Class Action Lawsuit: Levi & Korsinsky LLP has alerted investors about a pending class action aimed at recovering damages for those who purchased Erasca securities between January 14, 2025, and April 26, 2026, highlighting significant investor concerns regarding the company's disclosure practices.
- Disclosure Issues: The two corrective disclosures on April 27 and 28 revealed patent infringement allegations and a patient death in clinical trials, exposing misleading comparisons made by the company regarding ERAS-0015, which exacerbated investor losses.
- Investor Compensation Opportunities: Investors have until August 10, 2026, to apply for lead plaintiff status, and even those who do not apply can still participate in any recovery, indicating that the company's legal challenges may impact its future capital market performance.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following patent infringement allegations from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating a severe erosion of investor confidence in its ERAS-0015 product.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, alleging that the company misled investors between January 14, 2025, and April 26, 2026, potentially exposing investors to significant losses and highlighting the company's legal compliance risks.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's RMC-6236 and failing to disclose challenges to the validity of its intellectual property, which could undermine its competitive position in the market.
- Patient Safety Incident: Following treatment with ERAS-0015, a patient experienced an adverse event and subsequently died, further intensifying market concerns regarding the safety profile of Erasca's product and potentially prompting regulatory scrutiny.
See More
Erasca Faces Federal Securities Class Action Deadline
- Lawsuit Background: Erasca, Inc. is facing a federal securities class action for allegedly making false statements about its oncology drug ERAS-0015 during the class period from January 14, 2025, to April 26, 2026, failing to disclose improper comparisons with competitor RMC-6236, which may lead to patent and trade secret disputes.
- Stock Price Volatility: On April 27, 2026, Erasca's stock price dropped by $2.34, approximately 11%, from $21.49 to $19.15, following a patent infringement allegation from RevMed, indicating the market's sensitivity to legal risks associated with the company.
- Clinical Data Disclosure: On the same day, Erasca reported that a patient treated with ERAS-0015 died about a month after starting treatment, classified as a severe adverse reaction, which heightened investor concerns and led to a further decline of $9.25, or about 48%, in stock price the following day.
- Investor Action Advisory: Investors in Erasca are reminded to apply by August 10, 2026, to become lead plaintiffs in the pending class action, emphasizing the importance of timely action to protect their rights and interests in the litigation.
See More
Erasca Faces Securities Class Action After 48% Stock Plunge
- Stock Plunge: Erasca's stock plummeted by $9.25 (-48%) following allegations of patent infringement, resulting in a loss of over $2.8 billion in market capitalization, which severely undermines investor confidence and may trigger broader market concerns.
- Legal Action: Hagens Berman is investigating whether Erasca intentionally misled investors regarding the safety of ERAS-0015 and its competitive positioning in the oncology market, which could lead to further legal ramifications.
- Patent Dispute: The company is accused of improperly comparing its ERAS-0015 to Revolution Medicines' RMC-6236 without disclosing potential intellectual property disputes, which may impact future research and market strategies.
- Patient Incident: The disclosure of a patient's adverse event and subsequent death after receiving ERAS-0015 has intensified scrutiny over the product's safety profile, potentially leading to further regulatory investigations.
See More
Erasca Faces Class Action Lawsuit from Investors
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Erasca in the Southern District of California on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, alleging the company failed to disclose critical adverse facts that may have led to investor losses.
- False Statements Allegations: The lawsuit claims that Erasca made false and misleading statements regarding the preclinical data of ERAS-0015, asserting that improper comparisons to Revolution Medicines placed the company at risk of patent and trade secret violations, misleading investors about the drug's prospects.
- Stock Price Plummet: Following the disclosure on April 28, 2026, that Erasca received a letter from Revolution Medicines alleging patent infringement related to ERAS-0015, the stock price plummeted from $19.15 to $9.90, a decline of approximately 48%, significantly impacting investor confidence.
- Investor Action Encouraged: Affected investors are urged to apply by August 10, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering no-cost consultations to help investors understand their rights and options.
See More
Multiple Companies Face Class Action Lawsuits
- Via Transportation Class Action: From September 2025 to June 2026, Via Transportation is accused of failing to disclose a decline in annual recurring revenue per customer and regulatory issues, misleading investors about the company's prospects and potentially hindering its expansion strategy in Germany.
- Zillow Class Action: During the period from February 2025 to May 2026, Zillow allegedly failed to disclose that its agreement with Redfin was an acquisition rather than a partnership, increasing its exposure to antitrust legal risks, which could negatively impact the company's reputation and stock price.
- ADMA Biologics Class Action: From August 2024 to March 2026, ADMA is accused of engaging in undisclosed related party transactions and channel stuffing, leading to distorted financial reporting that could undermine investor confidence and future financing capabilities.
- Erasca Class Action: Between January 2025 and April 2026, Erasca is alleged to have failed to disclose improper comparisons in its preclinical data, risking violations of patent and trade secret protections, which could affect the company's future R&D and market competitiveness.
See More
Erasca Shares Plunge 53.9% Following Class Action Announcement
- Stock Price Collapse: Erasca's shares plummeted from $21.49 on April 24, 2026, to $9.90 by April 28, resulting in an $11.59 per share loss and a 53.9% decline, indicating a severe erosion of market confidence in the company's prospects.
- Class Action Lawsuit: Levi & Korsinsky LLP has alerted investors about a pending class action aimed at recovering damages for those who purchased Erasca securities between January 14, 2025, and April 26, 2026, highlighting significant investor concerns regarding the company's disclosure practices.
- Disclosure Issues: The two corrective disclosures on April 27 and 28 revealed patent infringement allegations and a patient death in clinical trials, exposing misleading comparisons made by the company regarding ERAS-0015, which exacerbated investor losses.
- Investor Compensation Opportunities: Investors have until August 10, 2026, to apply for lead plaintiff status, and even those who do not apply can still participate in any recovery, indicating that the company's legal challenges may impact its future capital market performance.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following patent infringement allegations from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating a severe erosion of investor confidence in its ERAS-0015 product.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, alleging that the company misled investors between January 14, 2025, and April 26, 2026, potentially exposing investors to significant losses and highlighting the company's legal compliance risks.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's RMC-6236 and failing to disclose challenges to the validity of its intellectual property, which could undermine its competitive position in the market.
- Patient Safety Incident: Following treatment with ERAS-0015, a patient experienced an adverse event and subsequently died, further intensifying market concerns regarding the safety profile of Erasca's product and potentially prompting regulatory scrutiny.
See More
